Carregant...
Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
BACKGROUND: Recent studies into the pathogenesis of psoriasis have identified the importance of interleukin 17 (IL-17) in disease activity and have thus provided a new target for biologic therapy. Ixekizumab, the most recent US Food and Drug Administration (FDA)-approved anti-IL-17 biologic agent, a...
Guardat en:
| Publicat a: | Clin Cosmet Investig Dermatol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5409192/ https://ncbi.nlm.nih.gov/pubmed/28461763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CCID.S111007 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|